Grants per year
- 1 - 25 out of 61 results
Search results
-
Active
Prot #1425-0003: A Phase IIa, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BI 706321 Orally Administered for 12 Weeks in Patients with Crohn`s Disease (CD) Receiving Ustekinu
Hanauer, S. B. (PD/PI)
Quintiles, Inc., Boehringer Ingelheim Pharmaceuticals, Inc.
1/17/24 → 1/17/27
Project: Research project
-
Prot #IM047029: A Phase 4, Prospective, Open‐label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clinical Practice
Hanauer, S. B. (PD/PI)
PPD Investigator Services, LLC, Celgene International II Sàrl
9/25/23 → 9/25/26
Project: Research project
-
: Prot #78934804CRD2001: A Phase 2b Randomized, Double‐blind, Active‐ and Placebo‐controlled, Parallel‐ group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Partici
Hanauer, S. B. (PD/PI)
Parexel, Janssen Research & Development, LLC
6/12/23 → 8/24/28
Project: Research project
-
Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Phase 3 Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial
Bonner, L. B. (PD/PI), Bonner, L. B. (PD/PI), Dulai, P. S. (PD/PI), Dulai, P. S. (PD/PI), Hanauer, S. B. (Co-Investigator), Hanauer, S. B. (Co-Investigator), Hanauer, S. B. (Co-Investigator), Hirano, I. (Co-Investigator), Hirano, I. (Co-Investigator), Scholtens, D. M. (Co-Investigator), Scholtens, D. M. (Co-Investigator), Sumagin, R. (Co-Investigator), Sumagin, R. (Co-Investigator), Sumagin, R. (Co-Investigator), Yang, G.-Y. (Co-Investigator), Yang, G.-Y. (Co-Investigator) & Yang, G.-Y. (Co-Investigator)
National Institute of Diabetes and Digestive and Kidney Diseases
3/15/23 → 2/29/28
Project: Research project
-
Prot #RCT01437: Proactive infliximab optimization using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: The OPTIMIZE Trial
Hanauer, S. B. (PD/PI) & Hanauer, S. B. (PD/PI)
Beth Israel Deaconess Medical Center, Leona M. and Harry B. Helmsley Charitable Trust
3/1/21 → 2/28/26
Project: Research project
-
GS-US-419-3896: A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease
Hanauer, S. B. (PD/PI)
PRA Health Sciences, Gilead Sciences, Inc
1/17/18 → 1/31/25
Project: Research project
-
Finished
Prot# Cx601-0303: A phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex
Bellaguarda, E. A. L. (PD/PI) & Hanauer, S. B. (Other)
7/30/21 → 7/30/24
Project: Research project
-
Advanced IBD 4th year Fellowship at Northwestern University in Chicago
Hanauer, S. B. (PD/PI)
3/29/21 → 6/30/22
Project: Research project
-
Translating Scientific Evidence into Practice using Digital Medicine and Electronic Patient Reported Outcomes
Bellaguarda, E. A. L. (PD/PI), Bass, M. (Co-Investigator) & Hanauer, S. B. (Co-Investigator)
Icahn School of Medicine at Mount Sinai, National Center for Advancing Translational Sciences
4/20/20 → 6/30/23
Project: Research project
-
Protocol I6T-MC-AMAN: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 1
Hanauer, S. B. (PD/PI)
Quintiles, Inc., Eli Lilly and Company
4/1/20 → 6/30/22
Project: Research project
-
Prot#SERES-201: ECO-RESET: A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to Moderate Ulcerative Colitis
Hanauer, S. B. (PD/PI)
Quintiles, Inc., Seres Therapeutics, Inc.
2/3/20 → 2/3/23
Project: Research project
-
Prot#RPC01-3203: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease”
Hanauer, S. B. (PD/PI)
ICON Clinical Research, LLC, Celgene International II Sàrl
9/9/19 → 9/9/24
Project: Research project
-
Prot#RPC01-3201: INDUCTION STUDY #1- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Cro
Hanauer, S. B. (PD/PI)
ICON Clinical Research, LLC, Celgene International II Sàrl
9/9/19 → 9/9/24
Project: Research project
-
Protocol M14-234: A Multicenter, Randomized, Double-Blind, Placebo -Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Bellaguarda, E. A. L. (PD/PI) & Hanauer, S. B. (PD/PI)
7/23/19 → 7/23/22
Project: Research project
-
Prot# SHP647-303: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Hanauer, S. B. (PD/PI)
PPD Investigator Services, LLC, Shire Human Genetic Therapies, Inc.
6/12/19 → 6/12/22
Project: Research project
-
Protocol SHP647-301: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Hanauer, S. B. (PD/PI)
PPD Investigator Services, LLC, Shire Human Genetic Therapies, Inc.
6/12/19 → 6/12/22
Project: Research project
-
Protocol 2017.008.01: Efficacy and safety of AbGn-168H in patients with moderate to severe active, anti-TNF and/or anti-integrin refractory ulcerative colitis: a 26-week, open-label, multi-center, hase II proof of principle trial
Hanauer, S. B. (PD/PI)
Parexel, AbGenomics International Inc.
1/29/19 → 1/29/22
Project: Research project
-
Prot#GS-US-418-4279: A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Ulcerative Colitis
Hanauer, S. B. (PD/PI)
PRA Health Sciences, Gilead Sciences, Inc
10/12/18 → 10/12/21
Project: Research project
-
Advanced IBD 4th year Fellowship at Northwestern University in Chicago
Hanauer, S. B. (PD/PI)
7/1/18 → 6/30/19
Project: Research project
-
Prot#APD371-004: A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects with Crohn’s Disease Experiencing Abdominal Pain
Hanauer, S. B. (PD/PI)
PPD Investigator Services, LLC, Arena Pharmaceuticals, Inc.
3/29/18 → 3/29/21
Project: Research project